Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era

Journal of Neuro-Oncology

Volumn 107, Issue 1, 2012, Pages 191-196

  Caffo, Orazio ^a   Gernone, Angela ^b   Ortega, Cinzia ^c   Sava, Teodoro ^d   Cartenì, Giacomo ^e   Facchini, Gaetano ^f   Re, Giovanni Lo ^g   Amadio, Placido ^h   Bortolus, Roberto ⁱ   Pagliarulo, Vincenzo ^j   Prati, Veronica ^c   Veccia, Antonello ^a   Galligioni, Enzo ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

^b Department of Medical Oncology   (Italy)

^c CANDIOLO CANCER INSTITUTE   (Italy)

^d Maggiore Hospital   (Italy)

^e CARDARELLI HOSPITAL   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^h GARIBALDI HOSPITAL   (Italy)

ⁱ CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^j UNIVERSITY OF BARI   (Italy)

more..

Author keywords

Brain metastases; Castration resistant prostate cancer; Chemotherapy; Docetaxel; Leptomeningeal metastases

Indexed keywords

DOCETAXEL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER CENTER; CANCER INCIDENCE; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG EFFICACY; HUMAN; HUMAN TISSUE; MALE; MENINGEAL METASTASIS; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE; ADENOCARCINOMA; BRAIN TUMOR; CHEMICALLY INDUCED DISORDER; FOLLOW UP; MENINGIOMA; METASTASIS; MIDDLE AGED; MORTALITY; NEOPLASM; ORCHIECTOMY; PATHOLOGY; PROSTATE TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FOLLOW-UP STUDIES; HUMANS; MALE; MENINGEAL NEOPLASMS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 84861697497     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0734-y     Document Type: Article

References (27)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
2. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765-781
3. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17:2506-2513
4. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764
5. Martel CL, Gumerlock PH, Meyers FJ, Lara PN (2003) Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 29:171-187
6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
7. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
8. Fitzpatrick JM, Sternberg CN, Saad F, Extermann M, Caffo O, Halabi S, Kramer G, Oudard S, de Wit R (2009) Treatment decisions for advanced genitourinary cancers: from symptoms to risk assessment. Eur Urol Suppl 8:738-746
9. Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C, Joly F, Priou F, Krakowski I, Zannetti A, Thill L, Beuzeboc P (2010) Docetaxel reintroduction in patients with metastatic castrationresistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 106:974-978
10. Mongan JP, Fadul CE, Cole BF, Zaki BI, Suriawinata AA, Ripple GH, Tosteson TD, Pipas JM (2009) Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer 8:100-105
11. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972-2977
12. Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75:5-14
13. McCutcheon IE, Eng DY, Logothetis CJ (1999) Brain metastasis from prostate carcinoma: antemortem recognition and outcome after treatment. Cancer 86:2301-2311
14. Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK (2003) Brain metastasis from prostate carcinoma: the M. D. Anderson Cancer Center experience. Cancer 98: 363-368
15. Salvati M, Frati A, Russo N, Brogna C, Piccirilli M, D'Andrea G, Occhiogrosso G, Pichierri A, Caroli E (2005) Brain metastasis from prostate cancer. Report of 13 cases and critical analysis of the literature. J Exp Clin Cancer Res 24:203-207
16. Catane R, Kaufman J, West C, Merrin C, Tsukada Y, Murphy GP (1976) Brain metastasis from prostatic carcinoma. Cancer 38:2583-2587
17. Taylor HG, Lefkowitz M, Skoog SJ, Miles BJ, McLeod DG, Coggin JT (1984) Intracranial metastases in prostate cancer. Cancer 53:2728-2730
18. Lin C, Turner S, Gurney H, Peduto A (2008) Increased detections of leptomeningeal presentations in men with hormone refractory prostate cancer: an effect of improved systemic therapy? J Med Imaging Radiat Oncol 52:376-381
19. Roberts-Thomson R, Rosenthal MA, Gonzales M, Drummond K (2009) Brain metastases in hormone refractory prostate cancer: a changing natural history? Intern Med J 39:205-206
20. Crivellari D, Pagani O, Veronesi A, Lombardi D, Nole F, Thurlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Sessa C, Goldhirsch A (2001) High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 12:353-356
21. van der Veldt AAM, Hendrikse NH, Smit EF, Mooijer MP, Rijnders AY, Gerritsen WR, van der Hoeven JJ, Windhorst AD, Lammertsma AA, Lubberink M (2010) Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients. Eur J Nucl Med Mol Imaging 37:1950-1958
22. Sanson M, Napolitano M, Yaya R, Keime-Guibert F, Broet P, Hoang-Xuan K, Delattre JY (2000) Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J Neurooncol 50:245-249
23. Sissung TM, Baum CE, Deeken J, Price DK, Ragon-Ching J, Steinberg SM, Dahut W, Sparreboom A, Figg WD (2008) ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 14:4543-4549
24. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698
25. Schinkel AH, Smit JJ, Van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, Berns AJM, Borst P (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502
26. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147-1154
27. Cisternino S, Bourasset F, Archimbaud Y, Semiond D, Sanderink G, Scherrmann JM (2003) Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol 138: 1367-1375